Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization.
Vascularization of the cornea occurs in many pathological conditions and can result in loss of visual acuity. It is also thought that vascularization predisposes the cornea to reject grafts by facilitating the detection of foreign antigens in donor material. A rat corneal assay for angiogenesis was adopted in the present study to evaluate the possible angiostatic activity of a low molecular weight heparan sulphate (LMW-HS). Corneal lesions were induced by chemical cauterization at 2 mm from the corneoscleral limbus. Rats were randomized to receive two drops/eye four times daily, for 6 days, of a solution of LMW-HS in vehicle (2.5% carboxymethylcellulose), heparin, heparin plus hydrocortisone, or vehicle alone. After a 6 day-treatment period, the eyes were perfused with india ink and the degree of neovascularization was evaluated. In rats treated with vehicle alone a dense vascular network extending from the corneoscleral limbus to the cauterized site was observed; on the contrary, a markedly reduced vascular network was evidenced in animals treated with LMW-HS. The distribution of basic fibroblast growth factor (bFGF) in the cauterized cornea was also evaluated by using an immunohistochemical method. A marked bFGF immunoreactivity was demonstrated in corneal epithelium and stroma of control rats 12-48 hours after the cautery. These results lead to the assumption that LMW-HS could be used in ophthalmology to inhibit corneal neovascularization.
Lepri
A
A
Institute of Ophthalmology, University of Pisa, Italy.
Benelli
U
U
Bernardini
N
N
Bianchi
F
F
Lupetti
M
M
Danesi
R
R
Del Tacca
M
M
Nardi
M
M
D000818:Animals; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism; D016510:Corneal Neovascularization / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D006854:Hydrocortisone / Q000008:administration & dosage / Q000494:pharmacology; D007124:Immunoenzyme Techniques; D008970:Molecular Weight; D009566:Nitrates; D009883:Ophthalmic Solutions; D017680:Potassium Compounds; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012835:Silver Nitrate
D016222:Fibroblast Growth Factor 2; D006493:Heparin; D006497:Heparan Sulfate; D006854:Hydrocortisone; D009566:Nitrates; D009883:Ophthalmic Solutions; D017680:Potassium Compounds; D012835:Silver Nitrate; C023844:potassium nitrate